nimotuzumab
oncoscience,biocon,daiichi sankyo
['nimotuzumab', 'pancreatic']
 "the addition of nimotuzumab to [gemcitabine] will provide benefit and great value to [patients with #pancreaticcancer], says shukui qin, md, phd, of cancer center of jinling hospital in china read more from the presentation at #asco22 here: 
The content you need, when you need it.